Aligos Therapeutics (ALGS) Return on Equity (2021 - 2025)
Aligos Therapeutics filings provide 5 years of Return on Equity readings, the most recent being 0.0% for Q4 2025.
- On a quarterly basis, Return on Equity rose 12.0% to 0.0% in Q4 2025 year-over-year; TTM through Dec 2025 was 0.0%, a 12.0% increase, with the full-year FY2025 number at 0.02%, up 2.0% from a year prior.
- Return on Equity hit 0.0% in Q4 2025 for Aligos Therapeutics, up from 0.01% in the prior quarter.
- In the past five years, Return on Equity ranged from a high of 0.0% in Q4 2025 to a low of 0.12% in Q4 2024.
- Median Return on Equity over the past 5 years was 0.01% (2023), compared with a mean of 0.02%.
- Biggest five-year swings in Return on Equity: decreased -11bps in 2024 and later rose 12bps in 2025.
- Aligos Therapeutics' Return on Equity stood at 0.01% in 2021, then crashed by -33bps to 0.01% in 2022, then plummeted by -40bps to 0.01% in 2023, then tumbled by -941bps to 0.12% in 2024, then soared by 97bps to 0.0% in 2025.
- The last three reported values for Return on Equity were 0.0% (Q4 2025), 0.01% (Q3 2025), and 0.01% (Q2 2025) per Business Quant data.